Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
Invitae test for hereditary cancers gains FDA de novo nod
Dive Brief: Genetic testing company Invitae has received de novo authorization from the Food and Drug Administration for an in vitro diagnostic test that can